ANNEXON, INC.

ANNX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Revenue
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $184.7M $119.4M $113.8M $112.5M $100.1M $49.3M $24.5M
SG&A Expense $31.7M $34.6M $30.0M $33.1M $30.6M $14.2M $8.0M
Operating Income $-216.4M $-154.1M $-143.7M $-145.6M $-130.7M $-63.5M $-32.5M
Operating Margin
Interest Expense
Pretax Income $-206.7M $-138.2M $134.2M $141.9M $130.3M $-63.4M $-37.2M
Income Tax Expense $0 $0 $0 $0 $4.0K
Net Income $-206.7M $-138.2M $-134.2M $-141.9M $-130.3M $-63.4M $-37.2M
Net Margin
EPS (Basic) $-1.34 $-1.01 $-1.77 $-2.60 $-3.40 $-4.15 $-88.30
EPS (Diluted) $-1.34 $-1.01 $-1.77 $-2.60 $-3.40 $-4.15 $-88.30
Shares Outstanding (Basic) 155.1M 137.4M 75.7M 54.7M 38.3M 38.2M 433.7K
Shares Outstanding (Diluted) 155.1M 137.4M 75.7M 54.7M 38.3M 38.2M 433.7K
Dividends Per Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00